Vietnam To Take Steps To Curb Sharp Increase In Drug Costs
This article was originally published in PharmAsia News
Executive Summary
The stability of Vietnam's drug prices has been shaken by a weaker Vietnamese currency coupled with an increase in the cost of imported drugs, the Drug Administration of Vietnam says. The Vietnam Pharmaceutical Companies Association said foreign drugs are expected to rise by as much as 10 percent because of the weaker dong against the U.S. dollar. The head of the Drugs Control Department of Vietnam said local drug companies invested less in their companies last year because of the decline in the economy, but said the DCD would take steps to discourage price increases by inviting more bids and licensing more makers. (Click here for more
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.